Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

Sixteen cycles of Brentuximab vedotin (BV) after autologous stem cell transplant (ASCT) in high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated an improved 2-year progression-free survival (PFS) over placebo. However, most patients are unable to complete all 16 cycles at full dose d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Charlotte B., Boucher, Ken, Nedved, Adrienne, Micallef, Ivana N., Desai, Sanjal, Hatic, Haris, Goyal, Gaurav, Zacholski, Erin, Fegley, Amanda, Sigmund, Audrey M., Bond, David A., Samuels, Courtney, Kamdar, Manali K., Aqeel, Sheeba Ba, Torka, Pallawi, MacDougall, Kira, Borogovac, Azra, Rajeeve, Sridevi, Sundaram, Suchitra, Fedak, Kalub, Modi, Dipenkumar, Travers, Elizabeth, Ayyappan, Sabarish, Chilakamarri, Nitin, Brem, Elizabeth A., Ermann, Daniel A., Fitzgerald, Lindsey A., Hu, Boyu, Stephens, Deborah M., Shah, Harsh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620571/
https://www.ncbi.nlm.nih.gov/pubmed/37102592
http://dx.doi.org/10.3324/haematol.2023.282780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620571/
https://www.ncbi.nlm.nih.gov/pubmed/37102592
http://dx.doi.org/10.3324/haematol.2023.282780

Ejemplares similares